PD-L1 expression as predictive biomarker in patients with NSCLC: a pooled analysis

BACKGROUND: Clinical trials of immune checkpoints modulators, including both programmed cell death-1 (PD-1) and programmed cell death-ligand 1 (PD-L1) inhibitors, have recently shown promising activity and tolerable toxicity in pre-treated NSCLC patients. However the predictive role of PD-L1 express...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:Oncotarget
Main Authors: Passiglia, Francesco, Bronte, Giuseppe, Bazan, Viviana, Natoli, Clara, Rizzo, Sergio, Galvano, Antonio, Listì, Angela, Cicero, Giuseppe, Rolfo, Christian, Santini, Daniele, Russo, Antonio
Format: Artigo
Jezik:Inglês
Izdano: Impact Journals LLC 2016
Teme:
Research Paper
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC4991415/
https://ncbi.nlm.nih.gov/pubmed/26918451
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.7582
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki